Are you over 18 and want to see adult content?
More Annotations
![A complete backup of https://cine.org](https://www.archivebay.com/archive6/images/d3d483d2-a484-43fd-b02f-eea174e0d43d.png)
A complete backup of https://cine.org
Are you over 18 and want to see adult content?
![A complete backup of https://biogas.org](https://www.archivebay.com/archive6/images/8a396986-fad0-404e-a583-adcadadfed4a.png)
A complete backup of https://biogas.org
Are you over 18 and want to see adult content?
![A complete backup of https://censo2020.mx](https://www.archivebay.com/archive6/images/c54498cf-85b5-4b00-97ed-bd674c4b71de.png)
A complete backup of https://censo2020.mx
Are you over 18 and want to see adult content?
![A complete backup of https://activewidgets.com](https://www.archivebay.com/archive6/images/0de7efaf-b744-41c1-ba68-2cae58ad741a.png)
A complete backup of https://activewidgets.com
Are you over 18 and want to see adult content?
![A complete backup of https://jobdig.com](https://www.archivebay.com/archive6/images/be9e9ee2-08fa-4755-9b33-cbbceaaf9920.png)
A complete backup of https://jobdig.com
Are you over 18 and want to see adult content?
![A complete backup of https://tomtommag.com](https://www.archivebay.com/archive6/images/6e33cc78-6aad-4fa7-ac7f-0fa3cb9f7cf6.png)
A complete backup of https://tomtommag.com
Are you over 18 and want to see adult content?
![A complete backup of https://doesgodexist.org](https://www.archivebay.com/archive6/images/01016cce-a15b-4fbc-8bcc-c5abb9c42cc2.png)
A complete backup of https://doesgodexist.org
Are you over 18 and want to see adult content?
![A complete backup of https://ahaparenting.com](https://www.archivebay.com/archive6/images/5e98017f-121f-4230-bd3f-39574cfa683b.png)
A complete backup of https://ahaparenting.com
Are you over 18 and want to see adult content?
![A complete backup of https://viaseptoday.com](https://www.archivebay.com/archive6/images/642560d3-84d1-40e3-bfa2-604c62c31c1a.png)
A complete backup of https://viaseptoday.com
Are you over 18 and want to see adult content?
![A complete backup of https://blueprintmedicines.com](https://www.archivebay.com/archive6/images/a219d80f-0dd2-43f2-970b-4d3819c11eab.png)
A complete backup of https://blueprintmedicines.com
Are you over 18 and want to see adult content?
![A complete backup of https://cloze.com](https://www.archivebay.com/archive6/images/2ca646c4-d74c-4ce4-a5cf-1915c5135139.png)
A complete backup of https://cloze.com
Are you over 18 and want to see adult content?
![A complete backup of https://grownyc.org](https://www.archivebay.com/archive6/images/0a0d9ee1-0015-4769-ba7b-732c1d541c2c.png)
A complete backup of https://grownyc.org
Are you over 18 and want to see adult content?
Favourite Annotations
![Numbers in Words - Convert Numbers to Words](https://www.archivebay.com/archive/a7c67f39-de9a-4e32-8089-8cf73910ef74.png)
Numbers in Words - Convert Numbers to Words
Are you over 18 and want to see adult content?
![A complete backup of minelistings.com](https://www.archivebay.com/archive/2128124f-f9eb-4834-a1f1-aefe537cc793.png)
A complete backup of minelistings.com
Are you over 18 and want to see adult content?
![Эти необыкновенные собачки – ЧИХУАХУА! (г.Владивосток)](https://www.archivebay.com/archive/00d31d22-ab26-4f19-b9b4-590b94348a04.png)
Эти необыкновенные собачки – ЧИХУАХУА! (г.Владивосток)
Are you over 18 and want to see adult content?
![Best Field Service Management Software & Mobile App - mHelpDesk](https://www.archivebay.com/archive/b743dfbd-6910-42e3-8fb2-49c3334073b1.png)
Best Field Service Management Software & Mobile App - mHelpDesk
Are you over 18 and want to see adult content?
![Portal 2 Sounds | A Portal 2 Soundboard containing all in-game quotes and dialog.](https://www.archivebay.com/archive/05c6233a-996d-4af7-8868-71c6702ce414.png)
Portal 2 Sounds | A Portal 2 Soundboard containing all in-game quotes and dialog.
Are you over 18 and want to see adult content?
![Ruutu | katso Vain elämää, tv-sarjat, elokuvat ja urheilua netissä | Ruutu](https://www.archivebay.com/archive/bcf1a213-a63d-4fa2-b314-4517c74dd30a.png)
Ruutu | katso Vain elämää, tv-sarjat, elokuvat ja urheilua netissä | Ruutu
Are you over 18 and want to see adult content?
![أكاديمية وعد|اربح فلوس من الانترنت|اربح فلوس مجانا](https://www.archivebay.com/archive/32b891d6-5c18-42de-9ed1-ff0bef7bcde4.png)
أكاديمية وعد|اربح فلوس من الانترنت|اربح فلوس مجانا
Are you over 18 and want to see adult content?
![CLIPARTO | Фотографии большого размера, 3D иллюстрации и векторный клипарт](https://www.archivebay.com/archive/d7b650ee-8d0b-4591-98fc-a3830f8f2099.png)
CLIPARTO | Фотографии большого размера, 3D иллюстрации и векторный клипарт
Are you over 18 and want to see adult content?
Text
mechanisms
GNS HEALTHCARE ANNOUNCES COLLABORATION TO POWER CANCER CAMBRIDGE, Mass.– June 19, 2017 – GNS Healthcare (GNS), a leading precision medicine company, today announced a collaboration with Genentech, a member of the Roche Group to leverage GNS REFS™ (Reverse Engineering and Forward Simulation) causal machine learning and simulation platform to power the development of novel cancertherapies.
CROSS-INDUSTRY COLLABORATION OF GNS HEALTHCARE, AMGEN AND Cross-Industry Collaboration of GNS Healthcare, Amgen and Alliance for Clinical Trials in Oncology to Leverage AI to Advance Understanding of Treatment Response in CAUSAL AI FOR TYPE 2 DIABETES Learn more about how Sanofi and GNS Healthcare used causal AI to identify predictors of hypoglycemia and other outcomes among patients with type 2 diabetes. THE PROMISE AND THE POWER OF IN SILICO CLINICAL TRIALS The way these in silico trials are built allows for a greater number and wider variety of experiments to be conducted, including head-to-head comparison studies, how a drug will perform in an out-of-sample patient cohort, and expand to possible new drug indications. By adopting in silico trials, biopharma has the ability to learn continuously ALL AI IS NOT EQUAL: WHY CAUSE AND EFFECT IS CRUCIAL FOR All AI Is Not Equal: Why Cause and Effect is Crucial for Healthcare. Judea Pearl is not happy. One of the pioneers of Artificial Intelligence in the 1980’s, Pearl said in a recent interview in The Atlantic that the field of AI is stuck in a world of reasoning by association and probabilistic predictions. HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINEGEMINI, THE IN SILICO PATIENTPARTNERINGTECHNOLOGYPUBLICATIONSNEWSCONTACT Understand the power of causal machine learning, why it’s different than other AI solutions and why it’s critical for healthcare. Learn more by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com GNS HEALTHCARE LAUNCHES GEMINI, THE FIRST IN SILICO A transformative innovation Gemini TM, the in silico patient, will drive better drug development, clinical trial design and generation of real-world evidence in multiple myeloma. GNS Healthcare, an AI-driven precision medicine company, today announced the launch of Gemini TM, the in silico multiple myeloma patient. The in silico patient is a highly accurate computer model of disease GNS HEALTHCARE WELCOMES EARL STEINBERG AS CHIEF OF HEALTH CAMBRIDGE, Mass.– April 14, 2020 – GNS Healthcare (GNS) is pleased to announce that Dr. Earl Steinberg, a nationally recognized expert in population health management, data analytics, and clinical informatics, has joined the company’s leadership team as a consultant to advance the company’s health plan offerings and drive clinical analytics efforts across GNS, particularly within THE POWER OF CAUSAL MACHINE LEARNING: GNS HEALTHCARE As a pioneer in machine learning and its application to healthcare, GNS brings an unparalleled depth and breadth of experience in leveraging AI to solve healthcare’s most crucial problems. Learn more about the power of causal machine learning by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINE Our core solution, Gemini — The in silico Patient™, is a data-driven ensemble of computer models linking drug treatment to patient characteristics to the complex molecular mechanisms and pathways driving clinical outcomes. Gemini simulates disease progression and drug response at the individual patient level to reveal responder vs. non-responder subpopulations and the underlyingmechanisms
GNS HEALTHCARE ANNOUNCES COLLABORATION TO POWER CANCER CAMBRIDGE, Mass.– June 19, 2017 – GNS Healthcare (GNS), a leading precision medicine company, today announced a collaboration with Genentech, a member of the Roche Group to leverage GNS REFS™ (Reverse Engineering and Forward Simulation) causal machine learning and simulation platform to power the development of novel cancertherapies.
CROSS-INDUSTRY COLLABORATION OF GNS HEALTHCARE, AMGEN AND Cross-Industry Collaboration of GNS Healthcare, Amgen and Alliance for Clinical Trials in Oncology to Leverage AI to Advance Understanding of Treatment Response in CAUSAL AI FOR TYPE 2 DIABETES Learn more about how Sanofi and GNS Healthcare used causal AI to identify predictors of hypoglycemia and other outcomes among patients with type 2 diabetes. THE PROMISE AND THE POWER OF IN SILICO CLINICAL TRIALS The way these in silico trials are built allows for a greater number and wider variety of experiments to be conducted, including head-to-head comparison studies, how a drug will perform in an out-of-sample patient cohort, and expand to possible new drug indications. By adopting in silico trials, biopharma has the ability to learn continuously ALL AI IS NOT EQUAL: WHY CAUSE AND EFFECT IS CRUCIAL FOR All AI Is Not Equal: Why Cause and Effect is Crucial for Healthcare. Judea Pearl is not happy. One of the pioneers of Artificial Intelligence in the 1980’s, Pearl said in a recent interview in The Atlantic that the field of AI is stuck in a world of reasoning by association and probabilistic predictions. GNS HEALTHCARE NEWS & EVENTS: HEALTHCARE ANALYTICS Want to see what we’ve been up to at GNS Healthcare? Check out our latest news, events and press releases. Learn more by contacting us today at 617-374-2300 or info@gnshealthcare.com HEALTHCARE CAREER & JOB OPPORTUNITIES: GNS HEALTHCARE Career Opportunities. GNS Healthcare has a simple philosophy: we transform healthcare with the best and the brightest stellar team. We are seeking smart, talented people who have a track record of success and a passion for creating change. We believe in teamwork and a collaborative, multidisciplinary culture are key to supercharging the HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINE Understand the power of causal machine learning, why it’s different than other AI solutions and why it’s critical for healthcare. Learn more by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com HEALTHCARE PEER REVIEWED JOURNAL ARTICLES: GNS HEALTHCARE Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson’s disease: a longitudinal cohort study and validation. September 25, 2017. Latourelle J, Beste M, Hadzi T, Miller R, Oppenheim J, Valko M, Wuest D, Church B, Khalil I, Hayete, B, Venuto C. Lancet Neurology Online. THE POWER OF CAUSAL MACHINE LEARNING: GNS HEALTHCARE As a pioneer in machine learning and its application to healthcare, GNS brings an unparalleled depth and breadth of experience in leveraging AI to solve healthcare’s most crucial problems. Learn more about the power of causal machine learning by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINE Gemini — The in silico Patient™, is the world’s most accurate computer model of multiple myeloma disease progression and drug response.Gemini simulates drug response at the individual patient level, rapidly identifying populations of patient responders and non-responders for clinical trial design. LEADERSHIP TEAM AT GNS HEALTHCARE Meet the team that is driving our mission to discover insights that cure disease and heal healthcare: our Leadership Team at GNS Healthcare. Learn more by contacting us today at 617-374-2300 or info@gnshealthcare.com SCIENCE: BIG BIOLOGICAL IMPACTS FROM BIG DATA Science: Big Biological Impacts From Big Data. In the life sciences, data can come in many forms, including information about genomic sequences, molecular pathways, and different populations of people. Those data create a potential bonanza, if scientists can overcome one stumbling block: how to handle the complexity of information. UNSTRUCTURED DATA: JOINING THE HEALTHCARE PARTY Unstructured data, which makes up the overwhelming majority of longitudinal data sets, is much harder to standardize and therefore harder to access, share and analyze. Unstructured data includes everything from email communications, physician clinical notes, patient phone call transcriptions, comment cards, wellness diary entries, lab reports THE PROMISE AND THE POWER OF IN SILICO CLINICAL TRIALS The way these in silico trials are built allows for a greater number and wider variety of experiments to be conducted, including head-to-head comparison studies, how a drug will perform in an out-of-sample patient cohort, and expand to possible new drug indications. By adopting in silico trials, biopharma has the ability to learn continuously HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINEGEMINI, THE IN SILICO PATIENTPARTNERINGTECHNOLOGYPUBLICATIONSNEWSCONTACT Understand the power of causal machine learning, why it’s different than other AI solutions and why it’s critical for healthcare. Learn more by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com GNS HEALTHCARE LAUNCHES GEMINI, THE FIRST IN SILICO A transformative innovation Gemini TM, the in silico patient, will drive better drug development, clinical trial design and generation of real-world evidence in multiple myeloma. GNS Healthcare, an AI-driven precision medicine company, today announced the launch of Gemini TM, the in silico multiple myeloma patient. The in silico patient is a highly accurate computer model of disease GNS HEALTHCARE WELCOMES EARL STEINBERG AS CHIEF OF HEALTH CAMBRIDGE, Mass.– April 14, 2020 – GNS Healthcare (GNS) is pleased to announce that Dr. Earl Steinberg, a nationally recognized expert in population health management, data analytics, and clinical informatics, has joined the company’s leadership team as a consultant to advance the company’s health plan offerings and drive clinical analytics efforts across GNS, particularly within THE POWER OF CAUSAL MACHINE LEARNING: GNS HEALTHCARE As a pioneer in machine learning and its application to healthcare, GNS brings an unparalleled depth and breadth of experience in leveraging AI to solve healthcare’s most crucial problems. Learn more about the power of causal machine learning by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINE Our core solution, Gemini — The in silico Patient™, is a data-driven ensemble of computer models linking drug treatment to patient characteristics to the complex molecular mechanisms and pathways driving clinical outcomes. Gemini simulates disease progression and drug response at the individual patient level to reveal responder vs. non-responder subpopulations and the underlyingmechanisms
GNS HEALTHCARE ANNOUNCES COLLABORATION TO POWER CANCER CAMBRIDGE, Mass.– June 19, 2017 – GNS Healthcare (GNS), a leading precision medicine company, today announced a collaboration with Genentech, a member of the Roche Group to leverage GNS REFS™ (Reverse Engineering and Forward Simulation) causal machine learning and simulation platform to power the development of novel cancertherapies.
CROSS-INDUSTRY COLLABORATION OF GNS HEALTHCARE, AMGEN AND Cross-Industry Collaboration of GNS Healthcare, Amgen and Alliance for Clinical Trials in Oncology to Leverage AI to Advance Understanding of Treatment Response in CAUSAL AI FOR TYPE 2 DIABETES Learn more about how Sanofi and GNS Healthcare used causal AI to identify predictors of hypoglycemia and other outcomes among patients with type 2 diabetes. THE PROMISE AND THE POWER OF IN SILICO CLINICAL TRIALS The way these in silico trials are built allows for a greater number and wider variety of experiments to be conducted, including head-to-head comparison studies, how a drug will perform in an out-of-sample patient cohort, and expand to possible new drug indications. By adopting in silico trials, biopharma has the ability to learn continuously ALL AI IS NOT EQUAL: WHY CAUSE AND EFFECT IS CRUCIAL FOR All AI Is Not Equal: Why Cause and Effect is Crucial for Healthcare. Judea Pearl is not happy. One of the pioneers of Artificial Intelligence in the 1980’s, Pearl said in a recent interview in The Atlantic that the field of AI is stuck in a world of reasoning by association and probabilistic predictions. HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINEGEMINI, THE IN SILICO PATIENTPARTNERINGTECHNOLOGYPUBLICATIONSNEWSCONTACT Understand the power of causal machine learning, why it’s different than other AI solutions and why it’s critical for healthcare. Learn more by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com GNS HEALTHCARE LAUNCHES GEMINI, THE FIRST IN SILICO A transformative innovation Gemini TM, the in silico patient, will drive better drug development, clinical trial design and generation of real-world evidence in multiple myeloma. GNS Healthcare, an AI-driven precision medicine company, today announced the launch of Gemini TM, the in silico multiple myeloma patient. The in silico patient is a highly accurate computer model of disease GNS HEALTHCARE WELCOMES EARL STEINBERG AS CHIEF OF HEALTH CAMBRIDGE, Mass.– April 14, 2020 – GNS Healthcare (GNS) is pleased to announce that Dr. Earl Steinberg, a nationally recognized expert in population health management, data analytics, and clinical informatics, has joined the company’s leadership team as a consultant to advance the company’s health plan offerings and drive clinical analytics efforts across GNS, particularly within THE POWER OF CAUSAL MACHINE LEARNING: GNS HEALTHCARE As a pioneer in machine learning and its application to healthcare, GNS brings an unparalleled depth and breadth of experience in leveraging AI to solve healthcare’s most crucial problems. Learn more about the power of causal machine learning by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINE Our core solution, Gemini — The in silico Patient™, is a data-driven ensemble of computer models linking drug treatment to patient characteristics to the complex molecular mechanisms and pathways driving clinical outcomes. Gemini simulates disease progression and drug response at the individual patient level to reveal responder vs. non-responder subpopulations and the underlyingmechanisms
GNS HEALTHCARE ANNOUNCES COLLABORATION TO POWER CANCER CAMBRIDGE, Mass.– June 19, 2017 – GNS Healthcare (GNS), a leading precision medicine company, today announced a collaboration with Genentech, a member of the Roche Group to leverage GNS REFS™ (Reverse Engineering and Forward Simulation) causal machine learning and simulation platform to power the development of novel cancertherapies.
CROSS-INDUSTRY COLLABORATION OF GNS HEALTHCARE, AMGEN AND Cross-Industry Collaboration of GNS Healthcare, Amgen and Alliance for Clinical Trials in Oncology to Leverage AI to Advance Understanding of Treatment Response in CAUSAL AI FOR TYPE 2 DIABETES Learn more about how Sanofi and GNS Healthcare used causal AI to identify predictors of hypoglycemia and other outcomes among patients with type 2 diabetes. THE PROMISE AND THE POWER OF IN SILICO CLINICAL TRIALS The way these in silico trials are built allows for a greater number and wider variety of experiments to be conducted, including head-to-head comparison studies, how a drug will perform in an out-of-sample patient cohort, and expand to possible new drug indications. By adopting in silico trials, biopharma has the ability to learn continuously ALL AI IS NOT EQUAL: WHY CAUSE AND EFFECT IS CRUCIAL FOR All AI Is Not Equal: Why Cause and Effect is Crucial for Healthcare. Judea Pearl is not happy. One of the pioneers of Artificial Intelligence in the 1980’s, Pearl said in a recent interview in The Atlantic that the field of AI is stuck in a world of reasoning by association and probabilistic predictions. GNS HEALTHCARE NEWS & EVENTS: HEALTHCARE ANALYTICS Want to see what we’ve been up to at GNS Healthcare? Check out our latest news, events and press releases. Learn more by contacting us today at 617-374-2300 or info@gnshealthcare.com HEALTHCARE CAREER & JOB OPPORTUNITIES: GNS HEALTHCARE Career Opportunities. GNS Healthcare has a simple philosophy: we transform healthcare with the best and the brightest stellar team. We are seeking smart, talented people who have a track record of success and a passion for creating change. We believe in teamwork and a collaborative, multidisciplinary culture are key to supercharging the HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINE Understand the power of causal machine learning, why it’s different than other AI solutions and why it’s critical for healthcare. Learn more by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com HEALTHCARE PEER REVIEWED JOURNAL ARTICLES: GNS HEALTHCARE Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson’s disease: a longitudinal cohort study and validation. September 25, 2017. Latourelle J, Beste M, Hadzi T, Miller R, Oppenheim J, Valko M, Wuest D, Church B, Khalil I, Hayete, B, Venuto C. Lancet Neurology Online. THE POWER OF CAUSAL MACHINE LEARNING: GNS HEALTHCARE As a pioneer in machine learning and its application to healthcare, GNS brings an unparalleled depth and breadth of experience in leveraging AI to solve healthcare’s most crucial problems. Learn more about the power of causal machine learning by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINE Gemini — The in silico Patient™, is the world’s most accurate computer model of multiple myeloma disease progression and drug response.Gemini simulates drug response at the individual patient level, rapidly identifying populations of patient responders and non-responders for clinical trial design. LEADERSHIP TEAM AT GNS HEALTHCARE Meet the team that is driving our mission to discover insights that cure disease and heal healthcare: our Leadership Team at GNS Healthcare. Learn more by contacting us today at 617-374-2300 or info@gnshealthcare.com SCIENCE: BIG BIOLOGICAL IMPACTS FROM BIG DATA Science: Big Biological Impacts From Big Data. In the life sciences, data can come in many forms, including information about genomic sequences, molecular pathways, and different populations of people. Those data create a potential bonanza, if scientists can overcome one stumbling block: how to handle the complexity of information. UNSTRUCTURED DATA: JOINING THE HEALTHCARE PARTY Unstructured data, which makes up the overwhelming majority of longitudinal data sets, is much harder to standardize and therefore harder to access, share and analyze. Unstructured data includes everything from email communications, physician clinical notes, patient phone call transcriptions, comment cards, wellness diary entries, lab reports THE PROMISE AND THE POWER OF IN SILICO CLINICAL TRIALS The way these in silico trials are built allows for a greater number and wider variety of experiments to be conducted, including head-to-head comparison studies, how a drug will perform in an out-of-sample patient cohort, and expand to possible new drug indications. By adopting in silico trials, biopharma has the ability to learn continuously HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINEGEMINI, THE IN SILICO PATIENTPARTNERINGTECHNOLOGYPUBLICATIONSNEWSCONTACT Understand the power of causal machine learning, why it’s different than other AI solutions and why it’s critical for healthcare. Learn more by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINE Our core solution, Gemini — The in silico Patient™, is a data-driven ensemble of computer models linking drug treatment to patient characteristics to the complex molecular mechanisms and pathways driving clinical outcomes. Gemini simulates disease progression and drug response at the individual patient level to reveal responder vs. non-responder subpopulations and the underlyingmechanisms
GNS HEALTHCARE LAUNCHES GEMINI, THE FIRST IN SILICO A transformative innovation Gemini TM, the in silico patient, will drive better drug development, clinical trial design and generation of real-world evidence in multiple myeloma. GNS Healthcare, an AI-driven precision medicine company, today announced the launch of Gemini TM, the in silico multiple myeloma patient. The in silico patient is a highly accurate computer model of disease THE POWER OF CAUSAL MACHINE LEARNING: GNS HEALTHCARE As a pioneer in machine learning and its application to healthcare, GNS brings an unparalleled depth and breadth of experience in leveraging AI to solve healthcare’s most crucial problems. Learn more about the power of causal machine learning by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com LEADERSHIP TEAM AT GNS HEALTHCARE Meet the team that is driving our mission to discover insights that cure disease and heal healthcare: our Leadership Team at GNS Healthcare. Learn more by contacting us today at 617-374-2300 or info@gnshealthcare.com GNS HEALTHCARE ANNOUNCES COLLABORATION TO POWER CANCER CAMBRIDGE, Mass.– June 19, 2017 – GNS Healthcare (GNS), a leading precision medicine company, today announced a collaboration with Genentech, a member of the Roche Group to leverage GNS REFS™ (Reverse Engineering and Forward Simulation) causal machine learning and simulation platform to power the development of novel cancertherapies.
CAUSAL AI FOR TYPE 2 DIABETES Learn more about how Sanofi and GNS Healthcare used causal AI to identify predictors of hypoglycemia and other outcomes among patients with type 2 diabetes. CROSS-INDUSTRY COLLABORATION OF GNS HEALTHCARE, AMGEN AND Cross-Industry Collaboration of GNS Healthcare, Amgen and Alliance for Clinical Trials in Oncology to Leverage AI to Advance Understanding of Treatment Response in ALL AI IS NOT EQUAL: WHY CAUSE AND EFFECT IS CRUCIAL FOR All AI Is Not Equal: Why Cause and Effect is Crucial for Healthcare. Judea Pearl is not happy. One of the pioneers of Artificial Intelligence in the 1980’s, Pearl said in a recent interview in The Atlantic that the field of AI is stuck in a world of reasoning by association and probabilistic predictions. THE PROMISE AND THE POWER OF IN SILICO CLINICAL TRIALS The way these in silico trials are built allows for a greater number and wider variety of experiments to be conducted, including head-to-head comparison studies, how a drug will perform in an out-of-sample patient cohort, and expand to possible new drug indications. By adopting in silico trials, biopharma has the ability to learn continuously HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINEGEMINI, THE IN SILICO PATIENTPARTNERINGTECHNOLOGYPUBLICATIONSNEWSCONTACT Understand the power of causal machine learning, why it’s different than other AI solutions and why it’s critical for healthcare. Learn more by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINE Our core solution, Gemini — The in silico Patient™, is a data-driven ensemble of computer models linking drug treatment to patient characteristics to the complex molecular mechanisms and pathways driving clinical outcomes. Gemini simulates disease progression and drug response at the individual patient level to reveal responder vs. non-responder subpopulations and the underlyingmechanisms
GNS HEALTHCARE LAUNCHES GEMINI, THE FIRST IN SILICO A transformative innovation Gemini TM, the in silico patient, will drive better drug development, clinical trial design and generation of real-world evidence in multiple myeloma. GNS Healthcare, an AI-driven precision medicine company, today announced the launch of Gemini TM, the in silico multiple myeloma patient. The in silico patient is a highly accurate computer model of disease THE POWER OF CAUSAL MACHINE LEARNING: GNS HEALTHCARE As a pioneer in machine learning and its application to healthcare, GNS brings an unparalleled depth and breadth of experience in leveraging AI to solve healthcare’s most crucial problems. Learn more about the power of causal machine learning by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com LEADERSHIP TEAM AT GNS HEALTHCARE Meet the team that is driving our mission to discover insights that cure disease and heal healthcare: our Leadership Team at GNS Healthcare. Learn more by contacting us today at 617-374-2300 or info@gnshealthcare.com GNS HEALTHCARE ANNOUNCES COLLABORATION TO POWER CANCER CAMBRIDGE, Mass.– June 19, 2017 – GNS Healthcare (GNS), a leading precision medicine company, today announced a collaboration with Genentech, a member of the Roche Group to leverage GNS REFS™ (Reverse Engineering and Forward Simulation) causal machine learning and simulation platform to power the development of novel cancertherapies.
CAUSAL AI FOR TYPE 2 DIABETES Learn more about how Sanofi and GNS Healthcare used causal AI to identify predictors of hypoglycemia and other outcomes among patients with type 2 diabetes. CROSS-INDUSTRY COLLABORATION OF GNS HEALTHCARE, AMGEN AND Cross-Industry Collaboration of GNS Healthcare, Amgen and Alliance for Clinical Trials in Oncology to Leverage AI to Advance Understanding of Treatment Response in ALL AI IS NOT EQUAL: WHY CAUSE AND EFFECT IS CRUCIAL FOR All AI Is Not Equal: Why Cause and Effect is Crucial for Healthcare. Judea Pearl is not happy. One of the pioneers of Artificial Intelligence in the 1980’s, Pearl said in a recent interview in The Atlantic that the field of AI is stuck in a world of reasoning by association and probabilistic predictions. THE PROMISE AND THE POWER OF IN SILICO CLINICAL TRIALS The way these in silico trials are built allows for a greater number and wider variety of experiments to be conducted, including head-to-head comparison studies, how a drug will perform in an out-of-sample patient cohort, and expand to possible new drug indications. By adopting in silico trials, biopharma has the ability to learn continuously GNS HEALTHCARE NEWS & EVENTS: HEALTHCARE ANALYTICS Want to see what we’ve been up to at GNS Healthcare? Check out our latest news, events and press releases. Learn more by contacting us today at 617-374-2300 or info@gnshealthcare.com HEALTHCARE CAREER & JOB OPPORTUNITIES: GNS HEALTHCARE Career Opportunities. GNS Healthcare has a simple philosophy: we transform healthcare with the best and the brightest stellar team. We are seeking smart, talented people who have a track record of success and a passion for creating change. We believe in teamwork and a collaborative, multidisciplinary culture are key to supercharging the CONTACT GNS HEALTHCARE: HEALTHCARE ANALYTICS & CAUSAL Find out more about what GNS Healthcare and causal machine learning can offer your life sciences or health plan company or foundation. Fill out our contact form, call us at 617-374-2300, or info@gnshealthcare.com. GNS HEALTHCARE CULTURE, PHILOSOPHY & HEALTHCARE JOB GNS Healthcare has a simple philosophy: we transform healthcare with the best and the brightest stellar team. Our employees are a diverse group- from cutting edge data scientists to savvy engineers to unparalleled project leads to physicists and just about everything in between. Learn more by contacting us today at 617-374-2300 or info@gnshealthcare.com HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINE Understand the power of causal machine learning, why it’s different than other AI solutions and why it’s critical for healthcare. Learn more by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com GNS HEALTHCARE WELCOMES EARL STEINBERG AS CHIEF OF HEALTH CAMBRIDGE, Mass.– April 14, 2020 – GNS Healthcare (GNS) is pleased to announce that Dr. Earl Steinberg, a nationally recognized expert in population health management, data analytics, and clinical informatics, has joined the company’s leadership team as a consultant to advance the company’s health plan offerings and drive clinical analytics efforts across GNS, particularly within HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINE Gemini — The in silico Patient™, is the world’s most accurate computer model of multiple myeloma disease progression and drug response.Gemini simulates drug response at the individual patient level, rapidly identifying populations of patient responders and non-responders for clinical trial design. LEADERSHIP TEAM AT GNS HEALTHCARE Meet the team that is driving our mission to discover insights that cure disease and heal healthcare: our Leadership Team at GNS Healthcare. Learn more by contacting us today at 617-374-2300 or info@gnshealthcare.com BOARD OF DIRECTORS AT GNS HEALTHCARE Read about our Board of Directors at GNS Healthcare. Learn more by contacting us today at 617-374-2300 or info@gnshealthcare.com THE PROMISE AND THE POWER OF IN SILICO CLINICAL TRIALS The way these in silico trials are built allows for a greater number and wider variety of experiments to be conducted, including head-to-head comparison studies, how a drug will perform in an out-of-sample patient cohort, and expand to possible new drug indications. By adopting in silico trials, biopharma has the ability to learn continuously HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINEGEMINI, THE IN SILICO PATIENTPARTNERINGTECHNOLOGYPUBLICATIONSNEWSCONTACT Understand the power of causal machine learning, why it’s different than other AI solutions and why it’s critical for healthcare. Learn more by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com GNS HEALTHCARE LAUNCHES GEMINI, THE FIRST IN SILICO A transformative innovation Gemini TM, the in silico patient, will drive better drug development, clinical trial design and generation of real-world evidence in multiple myeloma. GNS Healthcare, an AI-driven precision medicine company, today announced the launch of Gemini TM, the in silico multiple myeloma patient. The in silico patient is a highly accurate computer model of disease GNS HEALTHCARE WELCOMES EARL STEINBERG AS CHIEF OF HEALTH CAMBRIDGE, Mass.– April 14, 2020 – GNS Healthcare (GNS) is pleased to announce that Dr. Earl Steinberg, a nationally recognized expert in population health management, data analytics, and clinical informatics, has joined the company’s leadership team as a consultant to advance the company’s health plan offerings and drive clinical analytics efforts across GNS, particularly within THE POWER OF CAUSAL MACHINE LEARNING: GNS HEALTHCARE As a pioneer in machine learning and its application to healthcare, GNS brings an unparalleled depth and breadth of experience in leveraging AI to solve healthcare’s most crucial problems. Learn more about the power of causal machine learning by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINE Our core solution, Gemini — The in silico Patient™, is a data-driven ensemble of computer models linking drug treatment to patient characteristics to the complex molecular mechanisms and pathways driving clinical outcomes. Gemini simulates disease progression and drug response at the individual patient level to reveal responder vs. non-responder subpopulations and the underlyingmechanisms
GNS HEALTHCARE ANNOUNCES COLLABORATION TO POWER CANCER CAMBRIDGE, Mass.– June 19, 2017 – GNS Healthcare (GNS), a leading precision medicine company, today announced a collaboration with Genentech, a member of the Roche Group to leverage GNS REFS™ (Reverse Engineering and Forward Simulation) causal machine learning and simulation platform to power the development of novel cancertherapies.
CROSS-INDUSTRY COLLABORATION OF GNS HEALTHCARE, AMGEN AND Cross-Industry Collaboration of GNS Healthcare, Amgen and Alliance for Clinical Trials in Oncology to Leverage AI to Advance Understanding of Treatment Response in MULTIPLE MYELOMA DREAM CHALLENGE REVEALS EPIGENETIC and balanced accuracy curve (BAC). While the AUC is a widely accepted metric of prediction accuracy, it is sensitive to the specific time threshold used to differentiate high and ALL AI IS NOT EQUAL: WHY CAUSE AND EFFECT IS CRUCIAL FOR All AI Is Not Equal: Why Cause and Effect is Crucial for Healthcare. Judea Pearl is not happy. One of the pioneers of Artificial Intelligence in the 1980’s, Pearl said in a recent interview in The Atlantic that the field of AI is stuck in a world of reasoning by association and probabilistic predictions. THE PROMISE AND THE POWER OF IN SILICO CLINICAL TRIALS The way these in silico trials are built allows for a greater number and wider variety of experiments to be conducted, including head-to-head comparison studies, how a drug will perform in an out-of-sample patient cohort, and expand to possible new drug indications. By adopting in silico trials, biopharma has the ability to learn continuously HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINEGEMINI, THE IN SILICO PATIENTPARTNERINGTECHNOLOGYPUBLICATIONSNEWSCONTACT Understand the power of causal machine learning, why it’s different than other AI solutions and why it’s critical for healthcare. Learn more by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com GNS HEALTHCARE LAUNCHES GEMINI, THE FIRST IN SILICO A transformative innovation Gemini TM, the in silico patient, will drive better drug development, clinical trial design and generation of real-world evidence in multiple myeloma. GNS Healthcare, an AI-driven precision medicine company, today announced the launch of Gemini TM, the in silico multiple myeloma patient. The in silico patient is a highly accurate computer model of disease GNS HEALTHCARE WELCOMES EARL STEINBERG AS CHIEF OF HEALTH CAMBRIDGE, Mass.– April 14, 2020 – GNS Healthcare (GNS) is pleased to announce that Dr. Earl Steinberg, a nationally recognized expert in population health management, data analytics, and clinical informatics, has joined the company’s leadership team as a consultant to advance the company’s health plan offerings and drive clinical analytics efforts across GNS, particularly within THE POWER OF CAUSAL MACHINE LEARNING: GNS HEALTHCARE As a pioneer in machine learning and its application to healthcare, GNS brings an unparalleled depth and breadth of experience in leveraging AI to solve healthcare’s most crucial problems. Learn more about the power of causal machine learning by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINE Our core solution, Gemini — The in silico Patient™, is a data-driven ensemble of computer models linking drug treatment to patient characteristics to the complex molecular mechanisms and pathways driving clinical outcomes. Gemini simulates disease progression and drug response at the individual patient level to reveal responder vs. non-responder subpopulations and the underlyingmechanisms
GNS HEALTHCARE ANNOUNCES COLLABORATION TO POWER CANCER CAMBRIDGE, Mass.– June 19, 2017 – GNS Healthcare (GNS), a leading precision medicine company, today announced a collaboration with Genentech, a member of the Roche Group to leverage GNS REFS™ (Reverse Engineering and Forward Simulation) causal machine learning and simulation platform to power the development of novel cancertherapies.
CROSS-INDUSTRY COLLABORATION OF GNS HEALTHCARE, AMGEN AND Cross-Industry Collaboration of GNS Healthcare, Amgen and Alliance for Clinical Trials in Oncology to Leverage AI to Advance Understanding of Treatment Response in MULTIPLE MYELOMA DREAM CHALLENGE REVEALS EPIGENETIC and balanced accuracy curve (BAC). While the AUC is a widely accepted metric of prediction accuracy, it is sensitive to the specific time threshold used to differentiate high and ALL AI IS NOT EQUAL: WHY CAUSE AND EFFECT IS CRUCIAL FOR All AI Is Not Equal: Why Cause and Effect is Crucial for Healthcare. Judea Pearl is not happy. One of the pioneers of Artificial Intelligence in the 1980’s, Pearl said in a recent interview in The Atlantic that the field of AI is stuck in a world of reasoning by association and probabilistic predictions. THE PROMISE AND THE POWER OF IN SILICO CLINICAL TRIALS The way these in silico trials are built allows for a greater number and wider variety of experiments to be conducted, including head-to-head comparison studies, how a drug will perform in an out-of-sample patient cohort, and expand to possible new drug indications. By adopting in silico trials, biopharma has the ability to learn continuously GNS HEALTHCARE NEWS & EVENTS: HEALTHCARE ANALYTICS Want to see what we’ve been up to at GNS Healthcare? Check out our latest news, events and press releases. Learn more by contacting us today at 617-374-2300 or info@gnshealthcare.com HEALTHCARE CAREER & JOB OPPORTUNITIES: GNS HEALTHCARE Career Opportunities. GNS Healthcare has a simple philosophy: we transform healthcare with the best and the brightest stellar team. We are seeking smart, talented people who have a track record of success and a passion for creating change. We believe in teamwork and a collaborative, multidisciplinary culture are key to supercharging the GNS HEALTHCARE CULTURE, PHILOSOPHY & HEALTHCARE JOB GNS Healthcare has a simple philosophy: we transform healthcare with the best and the brightest stellar team. Our employees are a diverse group- from cutting edge data scientists to savvy engineers to unparalleled project leads to physicists and just about everything in between. Learn more by contacting us today at 617-374-2300 or info@gnshealthcare.com HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINE Understand the power of causal machine learning, why it’s different than other AI solutions and why it’s critical for healthcare. Learn more by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com THE POWER OF CAUSAL MACHINE LEARNING: GNS HEALTHCARE As a pioneer in machine learning and its application to healthcare, GNS brings an unparalleled depth and breadth of experience in leveraging AI to solve healthcare’s most crucial problems. Learn more about the power of causal machine learning by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com LEADERSHIP TEAM AT GNS HEALTHCARE Meet the team that is driving our mission to discover insights that cure disease and heal healthcare: our Leadership Team at GNS Healthcare. Learn more by contacting us today at 617-374-2300 or info@gnshealthcare.com CAUSAL MACHINE LEARNING: HEALTHCARE ARTIFICIAL REFS (Reverse Engineering, Forward Simulation) is different from other types of artificial intelligence platforms. It is a dynamic causal machine learning platform that discovers underlying cause and effect relationships in healthcare and grows smarter over time. Learn more by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com BOARD OF DIRECTORS AT GNS HEALTHCARE Read about our Board of Directors at GNS Healthcare. Learn more by contacting us today at 617-374-2300 or info@gnshealthcare.comGNS HEALTHCARE BLOG
By GNS Healthcare | AI , Future , Healthcare , Innovation , fda. The FDA's role has always been to balance safety and efficacy when it comes to approving drugs, medical devices and biological products. And yet the numbers are staggering, to bring a drug to market costs on average $2.7B and takes close to a THE PROMISE AND THE POWER OF IN SILICO CLINICAL TRIALS The way these in silico trials are built allows for a greater number and wider variety of experiments to be conducted, including head-to-head comparison studies, how a drug will perform in an out-of-sample patient cohort, and expand to possible new drug indications. By adopting in silico trials, biopharma has the ability to learn continuously HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINEGEMINI, THE IN SILICO PATIENTPARTNERINGTECHNOLOGYPUBLICATIONSNEWSCONTACT Understand the power of causal machine learning, why it’s different than other AI solutions and why it’s critical for healthcare. Learn more by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com GNS HEALTHCARE LAUNCHES GEMINI, THE FIRST IN SILICO A transformative innovation Gemini TM, the in silico patient, will drive better drug development, clinical trial design and generation of real-world evidence in multiple myeloma. GNS Healthcare, an AI-driven precision medicine company, today announced the launch of Gemini TM, the in silico multiple myeloma patient. The in silico patient is a highly accurate computer model of disease GNS HEALTHCARE WELCOMES EARL STEINBERG AS CHIEF OF HEALTH CAMBRIDGE, Mass.– April 14, 2020 – GNS Healthcare (GNS) is pleased to announce that Dr. Earl Steinberg, a nationally recognized expert in population health management, data analytics, and clinical informatics, has joined the company’s leadership team as a consultant to advance the company’s health plan offerings and drive clinical analytics efforts across GNS, particularly within THE POWER OF CAUSAL MACHINE LEARNING: GNS HEALTHCARE As a pioneer in machine learning and its application to healthcare, GNS brings an unparalleled depth and breadth of experience in leveraging AI to solve healthcare’s most crucial problems. Learn more about the power of causal machine learning by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINE Our core solution, Gemini — The in silico Patient™, is a data-driven ensemble of computer models linking drug treatment to patient characteristics to the complex molecular mechanisms and pathways driving clinical outcomes. Gemini simulates disease progression and drug response at the individual patient level to reveal responder vs. non-responder subpopulations and the underlyingmechanisms
GNS HEALTHCARE ANNOUNCES COLLABORATION TO POWER CANCER CAMBRIDGE, Mass.– June 19, 2017 – GNS Healthcare (GNS), a leading precision medicine company, today announced a collaboration with Genentech, a member of the Roche Group to leverage GNS REFS™ (Reverse Engineering and Forward Simulation) causal machine learning and simulation platform to power the development of novel cancertherapies.
CROSS-INDUSTRY COLLABORATION OF GNS HEALTHCARE, AMGEN AND Cross-Industry Collaboration of GNS Healthcare, Amgen and Alliance for Clinical Trials in Oncology to Leverage AI to Advance Understanding of Treatment Response in MULTIPLE MYELOMA DREAM CHALLENGE REVEALS EPIGENETIC and balanced accuracy curve (BAC). While the AUC is a widely accepted metric of prediction accuracy, it is sensitive to the specific time threshold used to differentiate high and ALL AI IS NOT EQUAL: WHY CAUSE AND EFFECT IS CRUCIAL FOR All AI Is Not Equal: Why Cause and Effect is Crucial for Healthcare. Judea Pearl is not happy. One of the pioneers of Artificial Intelligence in the 1980’s, Pearl said in a recent interview in The Atlantic that the field of AI is stuck in a world of reasoning by association and probabilistic predictions. THE PROMISE AND THE POWER OF IN SILICO CLINICAL TRIALS The way these in silico trials are built allows for a greater number and wider variety of experiments to be conducted, including head-to-head comparison studies, how a drug will perform in an out-of-sample patient cohort, and expand to possible new drug indications. By adopting in silico trials, biopharma has the ability to learn continuously HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINEGEMINI, THE IN SILICO PATIENTPARTNERINGTECHNOLOGYPUBLICATIONSNEWSCONTACT Understand the power of causal machine learning, why it’s different than other AI solutions and why it’s critical for healthcare. Learn more by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com GNS HEALTHCARE LAUNCHES GEMINI, THE FIRST IN SILICO A transformative innovation Gemini TM, the in silico patient, will drive better drug development, clinical trial design and generation of real-world evidence in multiple myeloma. GNS Healthcare, an AI-driven precision medicine company, today announced the launch of Gemini TM, the in silico multiple myeloma patient. The in silico patient is a highly accurate computer model of disease GNS HEALTHCARE WELCOMES EARL STEINBERG AS CHIEF OF HEALTH CAMBRIDGE, Mass.– April 14, 2020 – GNS Healthcare (GNS) is pleased to announce that Dr. Earl Steinberg, a nationally recognized expert in population health management, data analytics, and clinical informatics, has joined the company’s leadership team as a consultant to advance the company’s health plan offerings and drive clinical analytics efforts across GNS, particularly within THE POWER OF CAUSAL MACHINE LEARNING: GNS HEALTHCARE As a pioneer in machine learning and its application to healthcare, GNS brings an unparalleled depth and breadth of experience in leveraging AI to solve healthcare’s most crucial problems. Learn more about the power of causal machine learning by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINE Our core solution, Gemini — The in silico Patient™, is a data-driven ensemble of computer models linking drug treatment to patient characteristics to the complex molecular mechanisms and pathways driving clinical outcomes. Gemini simulates disease progression and drug response at the individual patient level to reveal responder vs. non-responder subpopulations and the underlyingmechanisms
GNS HEALTHCARE ANNOUNCES COLLABORATION TO POWER CANCER CAMBRIDGE, Mass.– June 19, 2017 – GNS Healthcare (GNS), a leading precision medicine company, today announced a collaboration with Genentech, a member of the Roche Group to leverage GNS REFS™ (Reverse Engineering and Forward Simulation) causal machine learning and simulation platform to power the development of novel cancertherapies.
CROSS-INDUSTRY COLLABORATION OF GNS HEALTHCARE, AMGEN AND Cross-Industry Collaboration of GNS Healthcare, Amgen and Alliance for Clinical Trials in Oncology to Leverage AI to Advance Understanding of Treatment Response in MULTIPLE MYELOMA DREAM CHALLENGE REVEALS EPIGENETIC and balanced accuracy curve (BAC). While the AUC is a widely accepted metric of prediction accuracy, it is sensitive to the specific time threshold used to differentiate high and ALL AI IS NOT EQUAL: WHY CAUSE AND EFFECT IS CRUCIAL FOR All AI Is Not Equal: Why Cause and Effect is Crucial for Healthcare. Judea Pearl is not happy. One of the pioneers of Artificial Intelligence in the 1980’s, Pearl said in a recent interview in The Atlantic that the field of AI is stuck in a world of reasoning by association and probabilistic predictions. THE PROMISE AND THE POWER OF IN SILICO CLINICAL TRIALS The way these in silico trials are built allows for a greater number and wider variety of experiments to be conducted, including head-to-head comparison studies, how a drug will perform in an out-of-sample patient cohort, and expand to possible new drug indications. By adopting in silico trials, biopharma has the ability to learn continuously GNS HEALTHCARE NEWS & EVENTS: HEALTHCARE ANALYTICS Want to see what we’ve been up to at GNS Healthcare? Check out our latest news, events and press releases. Learn more by contacting us today at 617-374-2300 or info@gnshealthcare.com HEALTHCARE CAREER & JOB OPPORTUNITIES: GNS HEALTHCARE Career Opportunities. GNS Healthcare has a simple philosophy: we transform healthcare with the best and the brightest stellar team. We are seeking smart, talented people who have a track record of success and a passion for creating change. We believe in teamwork and a collaborative, multidisciplinary culture are key to supercharging the GNS HEALTHCARE CULTURE, PHILOSOPHY & HEALTHCARE JOB GNS Healthcare has a simple philosophy: we transform healthcare with the best and the brightest stellar team. Our employees are a diverse group- from cutting edge data scientists to savvy engineers to unparalleled project leads to physicists and just about everything in between. Learn more by contacting us today at 617-374-2300 or info@gnshealthcare.com HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINE Understand the power of causal machine learning, why it’s different than other AI solutions and why it’s critical for healthcare. Learn more by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com THE POWER OF CAUSAL MACHINE LEARNING: GNS HEALTHCARE As a pioneer in machine learning and its application to healthcare, GNS brings an unparalleled depth and breadth of experience in leveraging AI to solve healthcare’s most crucial problems. Learn more about the power of causal machine learning by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com LEADERSHIP TEAM AT GNS HEALTHCARE Meet the team that is driving our mission to discover insights that cure disease and heal healthcare: our Leadership Team at GNS Healthcare. Learn more by contacting us today at 617-374-2300 or info@gnshealthcare.com CAUSAL MACHINE LEARNING: HEALTHCARE ARTIFICIAL REFS (Reverse Engineering, Forward Simulation) is different from other types of artificial intelligence platforms. It is a dynamic causal machine learning platform that discovers underlying cause and effect relationships in healthcare and grows smarter over time. Learn more by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com BOARD OF DIRECTORS AT GNS HEALTHCARE Read about our Board of Directors at GNS Healthcare. Learn more by contacting us today at 617-374-2300 or info@gnshealthcare.comGNS HEALTHCARE BLOG
By GNS Healthcare | AI , Future , Healthcare , Innovation , fda. The FDA's role has always been to balance safety and efficacy when it comes to approving drugs, medical devices and biological products. And yet the numbers are staggering, to bring a drug to market costs on average $2.7B and takes close to a THE PROMISE AND THE POWER OF IN SILICO CLINICAL TRIALS The way these in silico trials are built allows for a greater number and wider variety of experiments to be conducted, including head-to-head comparison studies, how a drug will perform in an out-of-sample patient cohort, and expand to possible new drug indications. By adopting in silico trials, biopharma has the ability to learn continuously HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINEGEMINI, THE IN SILICO PATIENTPARTNERINGTECHNOLOGYPUBLICATIONSNEWSCONTACT Understand the power of causal machine learning, why it’s different than other AI solutions and why it’s critical for healthcare. Learn more by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com GNS HEALTHCARE WELCOMES EARL STEINBERG AS CHIEF OF HEALTH CAMBRIDGE, Mass.– April 14, 2020 – GNS Healthcare (GNS) is pleased to announce that Dr. Earl Steinberg, a nationally recognized expert in population health management, data analytics, and clinical informatics, has joined the company’s leadership team as a consultant to advance the company’s health plan offerings and drive clinical analytics efforts across GNS, particularly within GNS HEALTHCARE LAUNCHES GEMINI, THE FIRST IN SILICO A transformative innovation Gemini TM, the in silico patient, will drive better drug development, clinical trial design and generation of real-world evidence in multiple myeloma. GNS Healthcare, an AI-driven precision medicine company, today announced the launch of Gemini TM, the in silico multiple myeloma patient. The in silico patient is a highly accurate computer model of disease THE POWER OF CAUSAL MACHINE LEARNING: GNS HEALTHCARECAUSAL MACHINE LEARNINGCAUSAL DEEP LEARNINGCAUSAL LEARNING INVESTIGATIONMACHINE LEARNING CAUSAL INFERENCECAUSAL LEARNING PROCESSCOLIN HILL GNSHEALTHCARE
As a pioneer in machine learning and its application to healthcare, GNS brings an unparalleled depth and breadth of experience in leveraging AI to solve healthcare’s most crucial problems. Learn more about the power of causal machine learning by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com LEADERSHIP TEAM AT GNS HEALTHCARE Meet the team that is driving our mission to discover insights that cure disease and heal healthcare: our Leadership Team at GNS Healthcare. Learn more by contacting us today at 617-374-2300 or info@gnshealthcare.com HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINE Our core solution, Gemini — The in silico Patient™, is a data-driven ensemble of computer models linking drug treatment to patient characteristics to the complex molecular mechanisms and pathways driving clinical outcomes. Gemini simulates disease progression and drug response at the individual patient level to reveal responder vs. non-responder subpopulations and the underlyingmechanisms
GNS HEALTHCARE ANNOUNCES COLLABORATION TO POWER CANCER CAMBRIDGE, Mass.– June 19, 2017 – GNS Healthcare (GNS), a leading precision medicine company, today announced a collaboration with Genentech, a member of the Roche Group to leverage GNS REFS™ (Reverse Engineering and Forward Simulation) causal machine learning and simulation platform to power the development of novel cancertherapies.
CROSS-INDUSTRY COLLABORATION OF GNS HEALTHCARE, AMGEN ANDGNS HEALTHCARE AIGNS HEALTHCARE INCGNS HEALTHCARE LEADERSHIPGNS HEALTHCARENEWS
Cross-Industry Collaboration of GNS Healthcare, Amgen and Alliance for Clinical Trials in Oncology to Leverage AI to Advance Understanding of Treatment Response in ALL AI IS NOT EQUAL: WHY CAUSE AND EFFECT IS CRUCIAL FOR All AI Is Not Equal: Why Cause and Effect is Crucial for Healthcare. Judea Pearl is not happy. One of the pioneers of Artificial Intelligence in the 1980’s, Pearl said in a recent interview in The Atlantic that the field of AI is stuck in a world of reasoning by association and probabilistic predictions. THE PROMISE AND THE POWER OF IN SILICO CLINICAL TRIALS The way these in silico trials are built allows for a greater number and wider variety of experiments to be conducted, including head-to-head comparison studies, how a drug will perform in an out-of-sample patient cohort, and expand to possible new drug indications. By adopting in silico trials, biopharma has the ability to learn continuously HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINEGEMINI, THE IN SILICO PATIENTPARTNERINGTECHNOLOGYPUBLICATIONSNEWSCONTACT Understand the power of causal machine learning, why it’s different than other AI solutions and why it’s critical for healthcare. Learn more by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com GNS HEALTHCARE WELCOMES EARL STEINBERG AS CHIEF OF HEALTH CAMBRIDGE, Mass.– April 14, 2020 – GNS Healthcare (GNS) is pleased to announce that Dr. Earl Steinberg, a nationally recognized expert in population health management, data analytics, and clinical informatics, has joined the company’s leadership team as a consultant to advance the company’s health plan offerings and drive clinical analytics efforts across GNS, particularly within GNS HEALTHCARE LAUNCHES GEMINI, THE FIRST IN SILICO A transformative innovation Gemini TM, the in silico patient, will drive better drug development, clinical trial design and generation of real-world evidence in multiple myeloma. GNS Healthcare, an AI-driven precision medicine company, today announced the launch of Gemini TM, the in silico multiple myeloma patient. The in silico patient is a highly accurate computer model of disease THE POWER OF CAUSAL MACHINE LEARNING: GNS HEALTHCARECAUSAL MACHINE LEARNINGCAUSAL DEEP LEARNINGCAUSAL LEARNING INVESTIGATIONMACHINE LEARNING CAUSAL INFERENCECAUSAL LEARNING PROCESSCOLIN HILL GNSHEALTHCARE
As a pioneer in machine learning and its application to healthcare, GNS brings an unparalleled depth and breadth of experience in leveraging AI to solve healthcare’s most crucial problems. Learn more about the power of causal machine learning by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com LEADERSHIP TEAM AT GNS HEALTHCARE Meet the team that is driving our mission to discover insights that cure disease and heal healthcare: our Leadership Team at GNS Healthcare. Learn more by contacting us today at 617-374-2300 or info@gnshealthcare.com HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINE Our core solution, Gemini — The in silico Patient™, is a data-driven ensemble of computer models linking drug treatment to patient characteristics to the complex molecular mechanisms and pathways driving clinical outcomes. Gemini simulates disease progression and drug response at the individual patient level to reveal responder vs. non-responder subpopulations and the underlyingmechanisms
GNS HEALTHCARE ANNOUNCES COLLABORATION TO POWER CANCER CAMBRIDGE, Mass.– June 19, 2017 – GNS Healthcare (GNS), a leading precision medicine company, today announced a collaboration with Genentech, a member of the Roche Group to leverage GNS REFS™ (Reverse Engineering and Forward Simulation) causal machine learning and simulation platform to power the development of novel cancertherapies.
CROSS-INDUSTRY COLLABORATION OF GNS HEALTHCARE, AMGEN ANDGNS HEALTHCARE AIGNS HEALTHCARE INCGNS HEALTHCARE LEADERSHIPGNS HEALTHCARENEWS
Cross-Industry Collaboration of GNS Healthcare, Amgen and Alliance for Clinical Trials in Oncology to Leverage AI to Advance Understanding of Treatment Response in ALL AI IS NOT EQUAL: WHY CAUSE AND EFFECT IS CRUCIAL FOR All AI Is Not Equal: Why Cause and Effect is Crucial for Healthcare. Judea Pearl is not happy. One of the pioneers of Artificial Intelligence in the 1980’s, Pearl said in a recent interview in The Atlantic that the field of AI is stuck in a world of reasoning by association and probabilistic predictions. THE PROMISE AND THE POWER OF IN SILICO CLINICAL TRIALS The way these in silico trials are built allows for a greater number and wider variety of experiments to be conducted, including head-to-head comparison studies, how a drug will perform in an out-of-sample patient cohort, and expand to possible new drug indications. By adopting in silico trials, biopharma has the ability to learn continuously GNS HEALTHCARE NEWS & EVENTS: HEALTHCARE ANALYTICS Want to see what we’ve been up to at GNS Healthcare? Check out our latest news, events and press releases. Learn more by contacting us today at 617-374-2300 or info@gnshealthcare.com HEALTHCARE CAREER & JOB OPPORTUNITIES: GNS HEALTHCARE Career Opportunities. GNS Healthcare has a simple philosophy: we transform healthcare with the best and the brightest stellar team. We are seeking smart, talented people who have a track record of success and a passion for creating change. We believe in teamwork and a collaborative, multidisciplinary culture are key to supercharging the GNS HEALTHCARE WELCOMES EARL STEINBERG AS CHIEF OF HEALTH CAMBRIDGE, Mass.– April 14, 2020 – GNS Healthcare (GNS) is pleased to announce that Dr. Earl Steinberg, a nationally recognized expert in population health management, data analytics, and clinical informatics, has joined the company’s leadership team as a consultant to advance the company’s health plan offerings and drive clinical analytics efforts across GNS, particularly within HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINE Understand the power of causal machine learning, why it’s different than other AI solutions and why it’s critical for healthcare. Learn more by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com CONTACT GNS HEALTHCARE: HEALTHCARE ANALYTICS & CAUSAL Find out more about what GNS Healthcare and causal machine learning can offer your life sciences or health plan company or foundation. Fill out our contact form, call us at 617-374-2300, or info@gnshealthcare.com. HEALTHCARE PEER REVIEWED JOURNAL ARTICLES: GNS HEALTHCARE Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson’s disease: a longitudinal cohort study and validation. September 25, 2017. Latourelle J, Beste M, Hadzi T, Miller R, Oppenheim J, Valko M, Wuest D, Church B, Khalil I, Hayete, B, Venuto C. Lancet Neurology Online. HEALTHCARE ARTIFICIAL INTELLIGENCE, CAUSAL MACHINE Gemini — The in silico Patient™, is the world’s most accurate computer model of multiple myeloma disease progression and drug response.Gemini simulates drug response at the individual patient level, rapidly identifying populations of patient responders and non-responders for clinical trial design. BOARD OF DIRECTORS AT GNS HEALTHCARE Read about our Board of Directors at GNS Healthcare. Learn more by contacting us today at 617-374-2300 or info@gnshealthcare.com CAUSAL MACHINE LEARNING: HEALTHCARE ARTIFICIAL REFS (Reverse Engineering, Forward Simulation) is different from other types of artificial intelligence platforms. It is a dynamic causal machine learning platform that discovers underlying cause and effect relationships in healthcare and grows smarter over time. Learn more by contacting GNS Healthcare today at 617-374-2300 or info@gnshealthcare.com THE PROMISE AND THE POWER OF IN SILICO CLINICAL TRIALS The way these in silico trials are built allows for a greater number and wider variety of experiments to be conducted, including head-to-head comparison studies, how a drug will perform in an out-of-sample patient cohort, and expand to possible new drug indications. By adopting in silico trials, biopharma has the ability to learn continuously* YouTube
* Blog
* Careers
* Partnering
* Technology
* Publications
* News
* In the News
* Events
* Press Releases
* Webinars
* Contact
Select Page
* Partnering
* Technology
* Publications
* News
* In the News
* Events
* Press Releases
* Webinars
* Contact
* Blog
* Careers
GNS Healthcare discovers which patients respond to drugs and why.LEARN MORE
GNS Healthcare accelerates the discovery and development of drugs to improve patient outcomes and significantly reduce total cost of patient care. Our causal AI technology integrates and transforms a wide variety of patient data types into _in silico_ patients which reveal the complex system of interactions underlying disease progression and drug response. The _in silico_ patients enable the simulation of drug response at the individual patient level across oncology, auto-immune, neurology, and cardio-metabolic disease in partnership with the world’s largest biopharma companies and healthplans.
HOW GNS PARTNERS WITH PHARMA AND PAYERS__
NOVEL SIMULATION FOR DISCOVERY AND TRANSLATIONAL RESEARCH Run _in silico_ simulations to determine intervention effects as well as reveal biomarkers of disease progression and drug response.__
FASTER, BETTER DESIGNED CLINICAL TRIALS Select optimal patient subpopulations for drugs and targets in development. Discover and evaluate the most promising hypotheses before study design, reducing expensive trial and error.__
ACCELERATED MARKET ACCESS Generate evidence of comparative effectiveness at later stages of drug development to support value-based contracts, support line of therapy positioning and label expansion.__
ADVANCED PAYER ANALYTICS Apply AI-drive models across lines of business to better predict rising patient risk and understand which patients are least likely to benefit from interventions or treatments.LATEST FROM GNS
GNS convenes industry luminaries Michael Bonney, Tom Daniel, Peter Neupert, and Lee Newcomer on_ in silico_ Patient Advisory Board.Read More
THE SCIENCE BEHIND THE SUCCESS Our AI approach has been shown to be the most powerful tool for treatment effectiveness simulation on an individual patient basis. Based on decades of breakthrough academic research, our _in silico _patients have been validated through over 50 peer-reviewed publications including in top-tier journals such as Lancet Neurology,Leukemia, and PLoS.
THE REFS™ PLATFORM The enabling technology behind GNS partners’ success is our patented REFS platform, the industry’s only platform that can go beyond predicting what may happen – to yield the deeper causal insight into _why_ something happens. The REFS platform has been refined over decades of development and validation, transform data into causal models that deliver insights rapidly and accurately.LEARN MORE
OUR PARTNERS
{"infinite":"true","pause_on_hover":"false","adaptive_height":"false","items":"5","auto_play":"true","speed":"1000","rtl_mode":"false","dots":"false","nav":"false","slides_to_scroll":"1","slides_to_scroll_mobile":"1","auto_play_speed":"1000","draggable":"true","swipe":"true","lazy":"false","carousel_mode":"standard","center_mode":"false","center_mode_padding":"60px","vertical":"false","nav_type":"nav_arrow","items_desktop":"4","items_desktop_small":"3","items_tablet":"2","items_mobile":"1","nav_arrow_type_horizon":"angle_arrow_horizon"} CONTACT GNS HEALTHCARECONTACT US
*
*
With the industry’s most validated AI technology and superior scientific expertise, GNS Healthcare enables you to rapidly uncover the unexpected insights that streamline and accelerate your most pressing clinical and market access priorities.*
* ABOUT US
* LEADERSHIP
* BOARD OF DIRECTORS * IN SILICO PATIENT ADVISORY BOARD*
* CAREERS
* POSITIONS
* CULTURE
*
* NEWSROOM
* BLOG
* EVENTS
* COVERAGE
*
* PRESS
* MEDIA KIT
* PRESS RELEASES
*
* CONTACT
* YouTube
READ BLOG
GNS Healthcare 196 Broadway, Cambridge, MA 02139 | 617-374-2300 This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. CookiesettingsACCEPT
Privacy & Cookies PolicyPRIVACY OVERVIEW
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic...Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. Necessary Always Enabled Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Non-necessary
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0